MD1004Y - Method for the treatment of infravesical obstruction caused by benign prostatic hyperplasia - Google Patents

Method for the treatment of infravesical obstruction caused by benign prostatic hyperplasia Download PDF

Info

Publication number
MD1004Y
MD1004Y MDS20150054A MDS20150054A MD1004Y MD 1004 Y MD1004 Y MD 1004Y MD S20150054 A MDS20150054 A MD S20150054A MD S20150054 A MDS20150054 A MD S20150054A MD 1004 Y MD1004 Y MD 1004Y
Authority
MD
Moldova
Prior art keywords
treatment
benign prostatic
prostatic hyperplasia
obstruction caused
infravesical obstruction
Prior art date
Application number
MDS20150054A
Other languages
Romanian (ro)
Russian (ru)
Inventor
Vitalie Ghicavîi
Original Assignee
Vitalie Ghicavîi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vitalie Ghicavîi filed Critical Vitalie Ghicavîi
Priority to MDS20150054A priority Critical patent/MD1004Z/en
Publication of MD1004Y publication Critical patent/MD1004Y/en
Publication of MD1004Z publication Critical patent/MD1004Z/en

Links

Landscapes

  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to medicine, in particular to urology and can be used for the treatment of infravesical obstruction caused by benign prostatic hyperplasia.According to the invention, the method consists in that once a day, per rectum, through microclysters is administered in a volume of 30 ml an ozonated mixture based on pumpkin oil, obtained by cold pressing, which contains 5 mg of zinc oxide and silver nanoparticles, taken in the ratio of 9:1, with the ozone concentration of 9000 µg/L and 5 mg of a 5-alpha-reductase inhibitor, then after 2.5 hours is completely emptied the urinary bladder and instilled 150 ml of an ozonated mixture based on amaranth oil, obtained by cold pressing with the ozone concentration of 10000 µg/L, which contains 5 mg of zinc oxide and silver nanoparticles, taken in the ratio of 9:1, the treatment course is 40 days.
MDS20150054A 2015-04-10 2015-04-10 Method for the treatment of infravesical obstruction caused by benign prostatic hyperplasia MD1004Z (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
MDS20150054A MD1004Z (en) 2015-04-10 2015-04-10 Method for the treatment of infravesical obstruction caused by benign prostatic hyperplasia

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MDS20150054A MD1004Z (en) 2015-04-10 2015-04-10 Method for the treatment of infravesical obstruction caused by benign prostatic hyperplasia

Publications (2)

Publication Number Publication Date
MD1004Y true MD1004Y (en) 2016-02-29
MD1004Z MD1004Z (en) 2016-09-30

Family

ID=55447198

Family Applications (1)

Application Number Title Priority Date Filing Date
MDS20150054A MD1004Z (en) 2015-04-10 2015-04-10 Method for the treatment of infravesical obstruction caused by benign prostatic hyperplasia

Country Status (1)

Country Link
MD (1) MD1004Z (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020125091A1 (en) * 2018-12-19 2020-06-25 湖南中科文泰生物科技有限公司 Sterol composition in pumpkin seed oil, application thereof, and drug for treating benign prostatic hyperplasia

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU1159578A1 (en) * 1981-06-22 1985-06-07 Запорожский государственный институт усовершенствования врачей им.М.Горького Method of treatment of prostate adenoma
SU1146066A1 (en) * 1983-06-17 1985-03-23 Центральный Ордена Трудового Красного Знамени Научно-Исследовательский Институт Курортологии И Физиотерапии Method of treatment of patients ill with prostate adenoma
SU1163859A1 (en) * 1983-12-23 1985-06-30 Министерство Здравоохранения Латвсср Method of testing chronic prosthatite
MD482G2 (en) * 1995-12-29 1997-05-31 Firma Svetskii & Co Continuous acted mixer
UA63883C2 (en) * 1997-10-30 2004-02-16 Петрушевський Іван Іванович Massaging device for preventing and treating adenoma of prostate
MD2788G2 (en) * 2004-07-28 2006-01-31 Государственный Медицинский И Фармацевтический Университет "Nicolae Testemitanu" Республики Молдова Entomologic anti-inflammatory and antioxidant preparation
MD2952G2 (en) * 2005-07-26 2006-08-31 Валериу РУДИК Medicinal remedy in the form of suppositories for prostatitis treatment
MD3426G2 (en) * 2007-02-02 2008-10-31 Виктор БОБУ Urological draining device
UA32566U (en) * 2007-12-06 2008-05-26 Харьковская Медицинская Академия Последипломного Образования Method for treatment of patients suffering from adenoma of prostate and chronic prostatitis
MD3804G2 (en) * 2008-07-08 2009-09-30 Виктор БОБУ Method for endourethral drainage in urological lower floor organs operations
MD4025C2 (en) * 2009-08-25 2010-10-31 Владимир КАРАУШ Remedy for treating prostatitis and prostate hyperplasia
RU2445000C2 (en) * 2010-03-22 2012-03-20 Общество с ограниченной ответственностью "ЭкоБиоФарм" Method of diagnosing oncologic diseases of prostate gland on basis of acylcarnitine and arachidonoyl amine
RU2481847C2 (en) * 2011-06-16 2013-05-20 Государственное образовательное учреждение высшего профессионального образования "Дагестанская государственная медицинская академия федерального агентства по здравоохранению и социальному развитию" Method of treating suppurative septic complications of prostate adenoma
MD4296C1 (en) * 2012-12-28 2015-03-31 Вячеслав ЧУХРИЙ Preparation from Tenebrio molitor larvae with antioxidant activity, process for its preparation and pharmaceutical product on its base

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020125091A1 (en) * 2018-12-19 2020-06-25 湖南中科文泰生物科技有限公司 Sterol composition in pumpkin seed oil, application thereof, and drug for treating benign prostatic hyperplasia

Also Published As

Publication number Publication date
MD1004Z (en) 2016-09-30

Similar Documents

Publication Publication Date Title
EP4272818A3 (en) Thrombolytic agent for the treatment of thromboembolism
MX2019005533A (en) Treatment for fibrosis.
PH12021551455A1 (en) Jak1 pathway inhibitors for the treatment of gastrointestinal disease
CA3256605A1 (en) Treating diseases using nitric oxide releasing solutions
MX2019006193A (en) Urogenital medical device formulation based on suitable biochemical compositions for the stabilization of the acidity and the redox state of the vaginal fluid.
WO2015095834A3 (en) Cancer treatments using erk1/2 and bcl-2 family inhibitors
MX2022012079A (en) METHODS AND COMPOSITIONS TO MAINTAIN KIDNEY HEALTH.
MX2016015437A (en) COMBINATION THAT INCLUDES A GLUCOCORTICOID AND EDO-S101.
WO2010103291A3 (en) Use of factor i for treating diseases involving the complement c3b feedback cycle
MX354981B (en) Medicine for treatment and/or improvement of sepsis.
MX2021003651A (en) Formulation comprising ozonised oil in the treatment of a tumour.
MX390196B (en) METHOD FOR MANUFACTURING A COMPOSITION COMPRISING A LOCAL ANESTHETIC, A HEPARINOID AND A PH REGULATOR.
AU2017261919A1 (en) Fat and medical uses thereof
PH12019501439B1 (en) Use of lactic acid bacteria to treat or prevent gestational diabetes mellitus
WO2019043176A3 (en) Hdac inhibitor in combination with antimetabolite agent for cancer therapy
MD1004Y (en) Method for the treatment of infravesical obstruction caused by benign prostatic hyperplasia
PE20191793A1 (en) METHOD FOR PREPARING A COMPOSITION WITH A LOW DISSOLVED OXYGEN CONTENT, INCLUDING PARACETAMOL, AND OPTIONALLY ONE OR MORE NSAIDS, AND A COMPOSITION OBTAINED FROM THE SAME
SG10201808038TA (en) Sildenafil Solutions and Methods of Making and Using Same
NZ774649A (en) Vibegron for the treatment of overactive bladder symptoms
EP2786765A3 (en) Composition for combination therapy comprising an anti-C-met antibody and a FGFR inhibitor
WO2011091154A3 (en) Use of human erythrocytes for prevention and treatment of cancer dissemination and growth
EP3587392A8 (en) Nanostructured formulations for the delivery of silibinin and other active ingredients for treating ocular diseases
WO2020055906A8 (en) Methods of treating cancer by inhibiting ubiquitin conjugating enzyme e2 k (ube2k)
WO2019040499A3 (en) Arf6 inhibitors and related methods
MD774Y (en) Endoscopic method for treating cirrhotic spontaneous ascites-peritonitis

Legal Events

Date Code Title Description
FG9Y Short term patent issued
KA4Y Short-term patent lapsed due to non-payment of fees (with right of restoration)